EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean-Emmanuel Kurtz iD, Eric Pujade-Lauraine iD, Ana Oaknin iD, Lisa Belin, Katharina Leitner iD, David Cibula iD, Hannelore Denys iD, Ora Rosengarten, Manuel Rodrigues iD, Nikolaus de Gregorio, Jeronimo Martinez García iD, Edgar Petru und 19 weitere

Journal of Clinical Oncology · 20.10.2023 · 41 (30) · 4768-4778

DOI: 10.1200/jco.23.00529 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.10.2023. Verfasst von Jean-Emmanuel Kurtz und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Oncology & Hematology, ICANS, Strasbourg, France. Hauptthemen laut MEDLINE: B7-H1 Antigen, Ovarian Neoplasms. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic with bevacizumab and chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), a placebo-controlled double-blinded randomized phase III trial, enrolled patients with recurrent epithelial OC, one to two previous chemotherapy lines, and PFI >6 months. Eligible patients were randomly assigned 2:1 to atezolizumab (1,200 mg once every 3 weeks or equivalent) or placebo for up to 24 months, combined with bevacizumab and six cycles of chemotherapy doublet, stratified by PFI, PD-L1 status, and chemotherapy regimen. Coprimary end points were investigator-assessed progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1–positive populations (alpha .025 for each population). RESULTS Between September 2016 and October 2019, 614 patients were randomly assigned: 410 to atezolizumab and 204 to placebo. Only 38% had PD-L1–positive tumors. After 3 years' median follow-up, the PFS difference between atezolizumab and placebo did not reach statistical significance in the ITT (hazard ratio [HR], 0.83; 95% CI, 0.69 to 0.99; P = .041; median 13.5 v 11.3 months, respectively) or PD-L1–positive (HR, 0.86; 95% CI, 0.63 to 1.16; P = .30; median 15.2 v 13.1 months, respectively) populations. The immature overall survival (OS) HR was 0.81 (95% CI, 0.65 to 1.01; median 35.5 v 30.6 months with atezolizumab v placebo, respectively). Global health-related quality of life did not differ between treatment arms. Grade ≥3 adverse events (AEs) occurred in 88% of atezolizumab-treated and 87% of placebo-treated patients; grade ≥3 AEs typical of immunotherapy were more common with atezolizumab (13% v 8%, respectively). CONCLUSION ATALANTE/ENGOT-ov29 did not meet its coprimary PFS objectives in the ITT or PD-L1–positive populations. OS follow-up continues. Further research on biopsy samples is warranted to decipher the immunologic landscape of late-relapsing OC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenOvarian NeoplasmsFemaleHumansAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Ovarian EpithelialNeoplasm Recurrence, LocalPlatinumQuality of LifeAntibodies, Monoclonal, Humanized

Substanzen

B7-H1 AntigenBevacizumabPlatinumatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical and Surgical Oncology & Hematology, ICANS, Strasbourg, France.
  • Association de Recherche sur les CAncers dont GYnécologiques (ARCAGY)-GINECO, Paris, France.
  • Gynaecologic Cancer Programme, Vall D'Hebron Institute of Oncology (VHIO), Hospital Universitario Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Biostatistics and Public Health Department, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié Salpětriére - C…
  • Gynecology and Obstetrics Department, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Obstetrics and Gynecology, General University Hospital in Prague, Charles University, Prague, Czech Republic.

ORCID-Profile: Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, Katharina Leitner, David Cibula, Hannelore Denys, Manuel Rodrigues, Jeronimo Martinez García, Roman Kocián, Ignace Vergote, Lydia Gaba, Stephan Polterauer, Florence Joly, Véronique D'Hondt, Coriolan Lebreton, Jean-Pierre Lotz, Pierre-Etienne Heudel, Florian Heitz

Zitieren

APA

Kurtz, J. E., Pujade-Lauraine, E., Oaknin, A., Belin, L., Leitner, K., Cibula, D., Denys, H., Rosengarten, O., Rodrigues, M., de Gregorio, N., Martinez García, J., Petru, E., Kocián, R., Vergote, I., Pautier, P., Schmalfeldt, B., Gaba, L., Polterauer, S., Mouret Reynier, M. A., …, & ATALANTE/ENGOT-ov29 Investigators (2023). Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. Journal of Clinical Oncology, 41(30), 4768-4778. https://doi.org/10.1200/jco.23.00529

Vancouver

Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, et al. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. Journal of Clinical Oncology. 2023;41(30):4768-4778. doi:10.1200/jco.23.00529

BibTeX
@article{Kurtz2023,
  author = {Kurtz, Jean-Emmanuel and Pujade-Lauraine, Eric and Oaknin, Ana and Belin, Lisa and Leitner, Katharina and Cibula, David and Denys, Hannelore and Rosengarten, Ora and Rodrigues, Manuel and de Gregorio, Nikolaus and Martinez García, Jeronimo and Petru, Edgar and Kocián, Roman and Vergote, Ignace and Pautier, Patricia and Schmalfeldt, Barbara and Gaba, Lydia and Polterauer, Stephan and Mouret Reynier, Marie-Ange and Sehouli, Jalid and Churruca, Cristina and Selle, Frédéric and Joly, Florence and D'Hondt, Véronique and Bultot-Boissier, Émilie and Lebreton, Coriolan and Lotz, Jean-Pierre and Largillier, Rémy and Heudel, Pierre-Etienne and Heitz, Florian and ATALANTE/ENGOT-ov29 Investigators, ATALANTE/ENGOT-ov29 Investigators},
  title = {Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {30},
  pages = {4768--4778},
  doi = {10.1200/jco.23.00529}
}
Kostenlos starten →